Friedenthal Financial Acquires Shares of 21,574 Moderna, Inc. $MRNA

Friedenthal Financial bought a new stake in shares of Moderna, Inc. (NASDAQ:MRNA) in the 1st quarter, Holdings Channel reports. The fund bought 21,574 shares of the company’s stock, valued at approximately $1,096,000.

Other institutional investors have also modified their holdings of the company. MUFG Securities EMEA plc purchased a new position in Moderna in the second quarter valued at about $28,000. Flagship Harbor Advisors LLC purchased a new stake in Moderna during the 4th quarter worth approximately $31,000. Ameriflex Group Inc. increased its holdings in Moderna by 3,775.0% during the 3rd quarter. Ameriflex Group Inc. now owns 1,240 shares of the company’s stock worth $32,000 after purchasing an additional 1,208 shares during the last quarter. Cromwell Holdings LLC increased its holdings in Moderna by 39.7% during the 4th quarter. Cromwell Holdings LLC now owns 1,200 shares of the company’s stock worth $35,000 after purchasing an additional 341 shares during the last quarter. Finally, EverSource Wealth Advisors LLC raised its position in shares of Moderna by 148.3% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,341 shares of the company’s stock valued at $37,000 after purchasing an additional 801 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Stock Performance

Shares of MRNA stock opened at $60.42 on Thursday. The company has a market cap of $23.97 billion, a P/E ratio of -7.41 and a beta of 1.05. The business has a 50 day moving average of $51.12 and a two-hundred day moving average of $46.13. Moderna, Inc. has a 52 week low of $22.28 and a 52 week high of $67.74. The company has a quick ratio of 2.35, a current ratio of 2.41 and a debt-to-equity ratio of 0.08.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Friday, May 1st. The company reported ($3.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($3.02) by ($0.38). The company had revenue of $389.00 million for the quarter, compared to analyst estimates of $236.37 million. Moderna had a negative return on equity of 26.64% and a negative net margin of 143.55%.During the same quarter in the previous year, the company posted ($2.52) earnings per share. The firm’s revenue for the quarter was up 260.2% compared to the same quarter last year. As a group, analysts anticipate that Moderna, Inc. will post -6.51 EPS for the current year.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Barclays raised their price target on shares of Moderna from $25.00 to $48.00 and gave the stock an “equal weight” rating in a research report on Thursday, April 2nd. Royal Bank Of Canada upped their price target on shares of Moderna from $35.00 to $38.00 and gave the company a “sector perform” rating in a report on Monday, May 4th. UBS Group reiterated a “neutral” rating on shares of Moderna in a research note on Tuesday, May 26th. Jefferies Financial Group reissued a “hold” rating on shares of Moderna in a report on Thursday, June 18th. Finally, The Goldman Sachs Group upped their target price on shares of Moderna from $43.00 to $49.00 and gave the company a “neutral” rating in a research note on Friday, May 1st. Two research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and five have issued a Sell rating to the stock. Based on data from MarketBeat.com, Moderna has an average rating of “Reduce” and an average price target of $36.60.

Insider Buying and Selling

In other news, President Stephen Hoge sold 53,336 shares of the business’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $51.37, for a total transaction of $2,739,870.32. Following the completion of the transaction, the president owned 1,483,848 shares of the company’s stock, valued at approximately $76,225,271.76. The trade was a 3.47% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Thyme Klinger sold 3,471 shares of the company’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $50.00, for a total transaction of $173,550.00. Following the transaction, the insider owned 67,468 shares of the company’s stock, valued at $3,373,400. This represents a 4.89% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 125,088 shares of company stock valued at $6,193,713 over the last three months. Corporate insiders own 10.80% of the company’s stock.

Moderna Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.